Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
|
CRANFORD, N.J., June 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that its CEO, Myron Holubiak, is scheduled to appear as a featured guest on TD Ameritrade Network's The Watch List with host Nicole Petallides on Tuesday, June 30, 2020 at 1:20pm ET. Interested parties may view the live interview at https://tdameritradenetwork.com/. The Watch List, hosted by with Nicole Petallides, highlights a panel of experts ranging from industry-leading CEOs, analysts, and Wall Street influencers to discuss pressing topics moving the market and is intended to provide viewers with a status update for the end of the trading day and beyond. Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. He was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research-based pharmaceutical company, from December 1998 to August 2001. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016. Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. ("Assembly") and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York's Centre for Health Economics. Ms. Petallides joined TD Ameritrade Network in December 2018 as a host based in New York City. Petallides was with FOX Business Network (FBN) where she anchored Fox Business Morning (2007) and FBN:AM (2016). For over a decade, she was the New York Stock Exchange (NYSE) floor correspondent appearing on Fox Business Network, Fox News Channel, Sky News and the syndicated program Top 30. Prior to joining FBN, she was an anchor at Bloomberg Television. About the TD Ameritrade Network About Citius Pharmaceuticals, Inc. About iMSC About Acute Respiratory Distress Syndrome (ARDS) Safe Harbor This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Contact: Andrew Scott
SOURCE Citius Pharmaceuticals, Inc. |
||
Company Codes: NASDAQ-SMALL:CTXR |
View original content: